The ultimate goal of the MIT/Mayo PS-OC is to develop a multiscale predictive model connecting non-invasive imaging (tissue scale) to predicted therapeutic distribution (tissue-cellular scale) and dynamic molecular cellular response (cellular-molecular scale). Beyond this over-arching goal, the Data Handling and Integration Core will provide key infrastructure to each Project through data management and storage, integration of diverse data types, and model construction. The Core will be led by Dr. Douglas Lauffenburger, an expert in systems biology and application of engineering principles to biological systems, with over twenty years of expertise in developing computational modeling techniques and applying these approaches to extract key biological insights from complex systems. Other members of the core include Dr. K. Dane Wittrup, an expert in protein engineering and quantitative pharmacology, Dr. Kristin Swanson, an expert in computational modeling with strong experience in extracting biological insight from non-invasive imaging techniques, and Dr. Nathalie Agar, an expert in MALDI-MSI, stimulated Raman spectroscopy, and imaging of drug distribution in brain tumors. Together, these investigators provide the requisite expertise and experience to fulfill each of the Core functions. The primary responsibilities of the core include: Core Task 1. Manage the data generated by the diverse array of analytical and physical biology methods that will be employed in Projects 1 and 2 and extract relevant information from the data files generated by each method. Core Task 2. Data integration and computational modeling. Core Task 3. Construction of a multiscale model predicting spatially resolved drug distribution and drug efficacy (molecular and cellular response to therapy) from non-invasive MR imaging.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA210180-05
Application #
9994238
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2016-08-29
Project End
2021-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Basu, Sankha S; Randall, Elizabeth C; Regan, Michael S et al. (2018) In Vitro Liquid Extraction Surface Analysis Mass Spectrometry (ivLESA-MS) for Direct Metabolic Analysis of Adherent Cells in Culture. Anal Chem 90:4987-4991
Randall, Elizabeth C; Emdal, Kristina B; Laramy, Janice K et al. (2018) Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun 9:4904
Roos, Alison; Dhruv, Harshil D; Peng, Sen et al. (2018) EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival. Mol Cancer Res 16:1185-1195
Rothenberg, Daniel A; Taliaferro, J Matthew; Huber, Sabrina M et al. (2018) A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth. iScience 9:367-381
Prahl, Louis S; Bangasser, Patrick F; Stopfer, Lauren E et al. (2018) Microtubule-Based Control of Motor-Clutch System Mechanics in Glioma Cell Migration. Cell Rep 25:2591-2604.e8
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Laramy, Janice K; Kim, Minjee; Gupta, Shiv K et al. (2017) Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther 363:136-147
Emdal, Kristina B; Dittmann, Antje; Reddy, Raven J et al. (2017) Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance. Mol Cancer Ther 16:2572-2585
Gampa, Gautham; Vaidhyanathan, Shruthi; Sarkaria, Jann N et al. (2017) Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res 123:10-25